Potential role of the corpus luteum in maternal cardiovascular adaptation to pregnancy and preeclampsia risk

Conrad, Kirk P.; Versen‐Höynck, Frauke von; Baker, Valerie L.

doi:10.1016/j.ajog.2021.08.018

Cited by 38 publications

(23 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If PE is not well controlled, it can progress to eclampsia. It is possible to develop a variety of complications that threaten the lives of mothers and children, including hemolysis, elevated creatinine levels, low platelet syndrome, placental abruption, multiple organ dysfunction, diffuse intravascular coagulation, fetal distress, fetal intrauterine growth restriction, and stillbirth ( 14 – 16 ). Worldwide, the incidence of PE fluctuates from 5 to 12%, and the mortality rate of patients with eclampsia can reach 1%.…”

Section: Discussionmentioning

confidence: 99%

The Mechanism of Downregulation of Twist1 Inhibiting Trophoblast Invasion and Aggravating the Development of Preeclampsia

Yang

Tong

2022

Front. Surg.

View full text Add to dashboard Cite

To study the expression of under expressed transcription factor Twist1 in preeclampsia (PE) and its effect on the invasion of placental trophoblast cells and to explore its related mechanism on the development of PE by establishing a pregnant rat model. Methods: the villi were collected from the induced abortion in the first trimester (6–8 weeks), the normal placenta (18–20 weeks) induced by the second trimester, the term placenta tissue of normal pregnancy (37–40 weeks), and the placental tissue of patients with PE, to detect the expression of Twist1. Trophoblast cells were subjected to primary culture in placental tissues of normal pregnant women and placental tissues of PE patients. The invasion ability of the two groups of trophoblasts was detected, and the primary cultured trophoblasts were divided into two groups: an experimental group and a control group. Specific Twist1 siRNA was added to the experimental group, and no reagents were added to the control group. The above-mentioned cells were given different interventions. To explore the effect of Twist1 on trophoblast cell invasion, cells were cultivated for 72 h. The SD rats were conceived. After the pregnancy was stable, the SD rats in different groups were treated with different treatments (interference with Twist1), and the average systolic blood pressure and urine protein of the gestational mothers in the different treatment groups were measured at 1 week, 2 weeks, and full-term pregnancy. The expression of Twist1 in the placenta tissue of SD rats with different interventions at full-term pregnancy was detected. The results showed that Twist1 expression is down-regulated in PE, and the invasion ability of placental trophoblast cells in PE patients is weak. After inhibiting Twist1, the mean tail artery pressure and urine protein level of SD pregnant rats increase, showing a trend of PE. The mechanism may be related to the inhibition of the placenta by Twist1 Trophoblast cell invasion.

show abstract

Section: Discussionmentioning

confidence: 99%

The Mechanism of Downregulation of Twist1 Inhibiting Trophoblast Invasion and Aggravating the Development of Preeclampsia

Yang

Tong

2022

Front. Surg.

View full text Add to dashboard Cite

show abstract

“…Due to an increasing number of publications warning of obstetrical complications related to the absence of the corpus luteum (85,86), the artificial cycle should probably be reserved for certain patients where no other alternatives are available for endometrial preparation. However, the artificial cycle remains the ideal setting to study the impact of serum luteal progesterone on pregnancy initiation, as its measurement is not disturbed by the corpus luteum and its highly changing endogenous secretion.…”

Section: Future Research Perspectivesmentioning

confidence: 99%

Low Luteal Serum Progesterone Levels Are Associated With Lower Ongoing Pregnancy and Live Birth Rates in ART: Systematic Review and Meta-Analyses

Ranisavljevic

Huberlant

Montagut³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Progesterone plays a key role in implantation. Several studies reported that lower luteal progesterone levels might be related to decreased chances of pregnancy. This systematic review was conducted using appropriate key words, on MEDLINE, EMBASE, and the Cochrane Library, from 1990 up to March 2021 to assess if luteal serum progesterone levels are associated with ongoing pregnancy (OP) and live birth (LB) rates (primary outcomes) and miscarriage rate (secondary outcome), according to the number of corpora lutea (CLs). Overall 2,632 non-duplicate records were identified, of which 32 relevant studies were available for quantitative analysis. In artificial cycles with no CL, OP and LB rates were significantly decreased when the luteal progesterone level falls below a certain threshold (risk ratio [RR] 0.72; 95% confidence interval [CI] 0.62–0.84 and 0.73; 95% CI 0.59–0.90, respectively), while the miscarriage rate was increased (RR 1.48; 95% CI 1.17–1.86). In stimulated cycles with several CLs, the mean luteal progesterone level in the no OP and no LB groups was significantly lower than in the OP and LB groups [difference in means 68.8 (95% CI 45.6–92.0) and 272.4 (95% CI 10.8–533.9), ng/ml, respectively]. Monitoring luteal serum progesterone levels could help in individualizing progesterone administration to enhance OP and LB rates, especially in cycles without corpus luteum.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=139019, identifier 139019.

show abstract

“…Relaxin is an endogenous 6kDa peptide hormone that is mainly produced by the corpus luteum (ovary) during pregnancy and in lower quantities by the brain, heart and kidney to mediate adaptive hemodynamic changes during pregnancy (enhancing cardiac output, renal blood flow, and arterial compliance) [ 109 , 110 , 111 ]. Relaxin is a member of the relaxin family of peptide hormones, which consists of three relaxin peptides found in the human body, the products of human gene-1 (H1), gene-2 (H2), and gene-3 (H3), relaxin, respectively [ 109 , 112 ].…”

Section: Strategies Used To Enhance Bm-msc-based Therapiesmentioning

confidence: 99%

“…Through the same pathway and the additional stimulation of inducible NOS (iNOS)–NO activity, RLX also promotes the expression and activity of various collagen-degrading MMPs to facilitate ECM degradation [ 129 , 131 ] ( Figure 5 ). In addition to its anti-fibrotic actions, RLX exerts angiogenic effects via its stimulation of VEGF and bFGF expression and activity and induces vasodilation by activating the endothelin receptor–NO signalling pathway [ 111 , 134 , 135 ]. Furthermore, RLX can therapeutically reduce the influx of various immune cells including granulocytes such as mast cells and neutrophils [ 136 ] in preclinical models of ischemia/reperfusion injury and inhibit macrophage infiltration in mice subjected to obstructive nephropathy- and hypertension-induced renal fibrosis [ 71 , 72 ].…”

Section: Strategies Used To Enhance Bm-msc-based Therapiesmentioning

confidence: 99%

Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease

Ricardo

Samuel

2022

IJMS

View full text Add to dashboard Cite

Chronic kidney disease (CKD) affects 1 in 10 members of the general population, placing these patients at an increasingly high risk of kidney failure. Despite the significant burden of CKD on various healthcare systems, there are no effective cures that reverse or even halt its progression. In recent years, human bone-marrow-derived mesenchymal stromal cells (BM-MSCs) have been recognised as a novel therapy for CKDs, owing to their well-established immunomodulatory and tissue-reparative properties in preclinical settings, and their promising safety profile that has been demonstrated in patients with CKDs from several clinical trials. However, renal fibrosis (scarring), a hallmark of CKD, has been shown to impair the viability and functionality of BM-MSCs post-transplantation. This has suggested that BM-MSCs might require a pre-treatment or adjunct therapy that can enhance the viability and therapeutic efficacy of these stromal cells in chronic disease settings. To address this, recent studies that have combined BM-MSCs with the anti-fibrotic drug serelaxin (RLX), have demonstrated the enhanced therapeutic potential of this combination therapy in normotensive and hypertensive preclinical models of CKD. In this review, a critical appraisal of the preclinical data available on the anti-fibrotic and renoprotective actions of BM-MSCs or RLX alone and when combined, as a treatment option for normotensive vs. hypertensive CKD, is discussed.

show abstract

Potential role of the corpus luteum in maternal cardiovascular adaptation to pregnancy and preeclampsia risk

Cited by 38 publications

References 92 publications

The Mechanism of Downregulation of Twist1 Inhibiting Trophoblast Invasion and Aggravating the Development of Preeclampsia

The Mechanism of Downregulation of Twist1 Inhibiting Trophoblast Invasion and Aggravating the Development of Preeclampsia

Low Luteal Serum Progesterone Levels Are Associated With Lower Ongoing Pregnancy and Live Birth Rates in ART: Systematic Review and Meta-Analyses

Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease

Contact Info

Product

Resources

About